Kazia Therapeutics CEO, Dr James Garner recently sat down with Boardroom Media in Sydney to discuss Kazia’s participation with the US National Cancer Institute backed Alliance for Clinical Trials in Oncology.
The National Cancer Institute is the leading cancer research organisation in the US, part of the US National Institute of Health.
The study, alongside US pharmaceutical giant Eli Lilly and biotechnology group Genentech, is for the treatment of cancer that has spread to the brain. Patients will be allocated to receive either GDC-0084 or drugs from Eli Lilly or Genentech, depending on the genetic profile of their tumour.
Importantly, initiation of this study brings the total number of ongoing clinical trials with GDC-0084 to four, each in different forms of brain cancer.
In the interview, Dr Garner discusses:
- Who the Alliance for Clinical Trials in Oncology is
- What the study will involve
- About brain metastases and the challenges involved in developing new treatments
- How the Alliance trial differs from Kazia’s own phase IIa study in GDC-0084
- How the Alliance study is an example of personalised medicine
Listen to the interview here.
You can also read the original ASX announcement on the study here.
About Kazia Therapeutics (ASX:KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.